ATE239787T1 - Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus - Google Patents
Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virusInfo
- Publication number
- ATE239787T1 ATE239787T1 AT94925691T AT94925691T ATE239787T1 AT E239787 T1 ATE239787 T1 AT E239787T1 AT 94925691 T AT94925691 T AT 94925691T AT 94925691 T AT94925691 T AT 94925691T AT E239787 T1 ATE239787 T1 AT E239787T1
- Authority
- AT
- Austria
- Prior art keywords
- hiv
- oligonucleotides
- immunodeficiency virus
- human immunodeficiency
- propagation
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract 10
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 4
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 abstract 2
- 229940124411 anti-hiv antiviral agent Drugs 0.000 abstract 2
- 230000003321 amplification Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9439093A | 1993-07-19 | 1993-07-19 | |
| PCT/US1994/008407 WO1995003407A2 (en) | 1993-07-19 | 1994-07-19 | Oligonucleotides with activity against human immunodeficiency virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE239787T1 true ATE239787T1 (de) | 2003-05-15 |
Family
ID=22244881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94925691T ATE239787T1 (de) | 1993-07-19 | 1994-07-19 | Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5629413A (de) |
| EP (1) | EP0714436B1 (de) |
| JP (1) | JPH09501562A (de) |
| KR (1) | KR960704033A (de) |
| AT (1) | ATE239787T1 (de) |
| AU (1) | AU688364B2 (de) |
| CA (1) | CA2166889C (de) |
| DE (1) | DE69432635D1 (de) |
| WO (1) | WO1995003407A2 (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE239787T1 (de) * | 1993-07-19 | 2003-05-15 | Gen Probe Inc | Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus |
| US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5916777A (en) * | 1995-06-07 | 1999-06-29 | Gen-Probe Incorporated | Enzymatic synthesis of oligonucleotides using 3'-ribonucleotide primers |
| US5932450A (en) * | 1995-06-07 | 1999-08-03 | Gen-Probe Incorporated | Enzymatic synthesis of oligonucleotides using digestible templates |
| US5652126A (en) * | 1995-06-07 | 1997-07-29 | Gen-Probe Incorporated | Use of restriction endonuclease sequences for cleaving phosphorothioate oligonucleotides |
| US5711964A (en) * | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
| US5759519A (en) * | 1995-06-07 | 1998-06-02 | Gen-Probe Incorporated | Method for the intracellular delivery of biomolecules using thiocationic lipids |
| US5739271A (en) * | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Thiocationic lipids |
| US5739311A (en) * | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Enzymatic synthesis of phosphorothioate oligonucleotides using restriction endonucleases |
| US5851548A (en) * | 1995-06-07 | 1998-12-22 | Gen-Probe Incorporated | Liposomes containing cationic lipids and vitamin D |
| US5756352A (en) * | 1995-06-07 | 1998-05-26 | Gen-Probe Incorporated | Thiocationic lipid-nucleic acid conjugates |
| US20020022261A1 (en) * | 1995-06-29 | 2002-02-21 | Anderson Rolfe C. | Miniaturized genetic analysis systems and methods |
| US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
| ES2153807T3 (es) * | 1997-08-08 | 2005-06-16 | Biomerieux B.V. | Secuencias de acido nucleico que se pueden utilizar como cebadores y sondas en la amplificacion y deteccion de todos los subtipos de vih-1. |
| WO2000020576A2 (en) * | 1998-10-02 | 2000-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health | Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein |
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| EP1141314A2 (de) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Für antigene polypeptide des hiv type c kodierende polynukleotide, entsprechende polypeptide und verwendungen davon |
| AU3219400A (en) * | 1999-02-03 | 2000-08-25 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and reagents for molecular detection of hiv-1 groups m, n and |
| DE19908766C2 (de) * | 1999-02-19 | 2001-02-15 | Ulrich Schubert | Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien |
| US6787303B1 (en) * | 1999-04-01 | 2004-09-07 | Alton Ochsner Medical Foundation | Identification of a novel retrovirus associated with primary sclerosing cholangitis and autoimmune hepatitis |
| US6258593B1 (en) * | 1999-06-30 | 2001-07-10 | Agilent Technologies Inc. | Apparatus for conducting chemical or biochemical reactions on a solid surface within an enclosed chamber |
| AU781934B2 (en) * | 1999-07-09 | 2005-06-23 | Gen-Probe Incorporated | Detection of HIV-1 by nucleic acid amplification |
| US6582920B2 (en) | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| EA007232B1 (ru) | 2001-08-17 | 2006-08-25 | Коли Фармасьютикал Гмбх | Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| JP2005527198A (ja) * | 2002-02-14 | 2005-09-15 | シティ・オブ・ホープ | 哺乳動物細胞において、干渉ｒｎａ分子を産生する方法、および該干渉ｒｎａ分子の療法的使用 |
| US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| NZ540098A (en) | 2002-10-29 | 2008-09-26 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
| JP2004283024A (ja) * | 2003-03-19 | 2004-10-14 | Junsei Chemical Co Ltd | 新規アンチセンスオリゴヌクレオチド及び抗ｈｉｖ剤 |
| WO2011005220A1 (en) * | 2009-07-07 | 2011-01-13 | Masafumi Inoue | Human immunodeficiency virus type 1 (hiv-1) detection method and kit therefor |
| CA2930558A1 (en) | 2013-11-14 | 2015-05-21 | The General Hospital Corporation | Suicide contrast agents targeting hiv reservoirs for theranostic erradication |
| US12674163B2 (en) | 2020-11-04 | 2026-07-07 | Ahmed Ibrahim Mohamed Ibrahim | Comb shaped antivirals ending with or without chain terminating bases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023243A (en) * | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| JPS60501339A (ja) * | 1983-01-10 | 1985-08-22 | ジエン−プロ−ブ インコ−ポレィテッド | 生物を検出、同定又は定量する方法およびキット |
| NZ209840A (en) * | 1983-10-17 | 1988-11-29 | Kaji Akira | A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action |
| US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5208149A (en) * | 1983-10-20 | 1993-05-04 | The Research Foundation Of State University Of New York | Nucleic acid constructs containing stable stem and loop structures |
| US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
| US5264423A (en) * | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5110802A (en) * | 1987-07-14 | 1992-05-05 | City Of Hope | Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates |
| WO1989002476A1 (en) * | 1987-09-21 | 1989-03-23 | Ml Technology Ventures, L.P. | Homogeneous protection assay |
| PT88665B (pt) * | 1987-10-05 | 1992-12-31 | Ml Tecnology Ventures Lp | Metodo para a marcacao com ester de acridinio e purificacao de sondas nucleotidicas |
| DE3907562A1 (de) * | 1989-03-09 | 1990-09-13 | Bayer Ag | Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung |
| IE20010427A1 (en) * | 1990-04-10 | 2003-03-05 | Canji Inc | Gene therapy for cell proliferative diseases |
| US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| ES2124231T3 (es) * | 1990-10-26 | 1999-02-01 | Genta Inc | Procedimiento mejorado para sintesis de oligomeros. |
| JPH09500787A (ja) * | 1993-07-19 | 1997-01-28 | ジェン−プローブ・インコーポレイテッド | 蛋白生産、細胞増殖および／または感染症病原体の増殖に対するオリゴヌクレオチド阻害の促進 |
| ATE239787T1 (de) * | 1993-07-19 | 2003-05-15 | Gen Probe Inc | Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus |
-
1994
- 1994-07-19 AT AT94925691T patent/ATE239787T1/de not_active IP Right Cessation
- 1994-07-19 KR KR1019960700256A patent/KR960704033A/ko not_active Ceased
- 1994-07-19 DE DE69432635T patent/DE69432635D1/de not_active Expired - Lifetime
- 1994-07-19 JP JP7505391A patent/JPH09501562A/ja active Pending
- 1994-07-19 US US08/279,751 patent/US5629413A/en not_active Expired - Lifetime
- 1994-07-19 AU AU75511/94A patent/AU688364B2/en not_active Ceased
- 1994-07-19 CA CA002166889A patent/CA2166889C/en not_active Expired - Fee Related
- 1994-07-19 WO PCT/US1994/008407 patent/WO1995003407A2/en not_active Ceased
- 1994-07-19 EP EP94925691A patent/EP0714436B1/de not_active Expired - Lifetime
-
1997
- 1997-06-02 US US08/866,958 patent/US5919701A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0714436B1 (de) | 2003-05-07 |
| JPH09501562A (ja) | 1997-02-18 |
| US5919701A (en) | 1999-07-06 |
| WO1995003407A3 (en) | 1995-06-22 |
| CA2166889A1 (en) | 1995-02-02 |
| CA2166889C (en) | 2001-09-11 |
| US5629413A (en) | 1997-05-13 |
| KR960704033A (ko) | 1996-08-31 |
| AU7551194A (en) | 1995-02-20 |
| DE69432635D1 (de) | 2003-06-12 |
| EP0714436A1 (de) | 1996-06-05 |
| WO1995003407A2 (en) | 1995-02-02 |
| AU688364B2 (en) | 1998-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69432635D1 (de) | Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus | |
| Witvrouw et al. | Novel inhibitors of HIV-1 integration | |
| CA2173328A1 (en) | HIV Protease Inhibitors | |
| DE69528867D1 (de) | Verbindungen und Verfahren zur Inhibierung der Verbreitung der HIV | |
| CA2299275A1 (en) | Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of hiv-1 | |
| CA2159103A1 (en) | Detection of human immunodeficiency virus type 1 | |
| HUP0002224A1 (hu) | Virusellenes hatású benzimidazol-származékok | |
| CY1112171T1 (el) | Μτβ32α αντιγονο μυκοβακτηριδιου της φυματιωσης με απενεργοποιημενη δραστικη θεση και πρωτεϊνες συντηξης αυτου | |
| DE60023300D1 (de) | Verwendung von cpg als adjuvans für hivimpstoff | |
| ES2151600T3 (es) | Derivados de n-(3-amino-2-hidroxibutil)sulfonamida utilizados como inhibidores de proteasa de vih. | |
| EP0404625A3 (de) | Oligonukleotiden-Sequenzen zur Amplifizierung von HIV-2 und SIV Retrovirusgenomen, ihre Verwendung zur In-vitro-Diagnostik von durch diese Viren verursachten Infektionen | |
| Machado et al. | Antiviral activity and resistance profile of phosphazid-a novel prodrug of AZT | |
| Konings et al. | Protease mutations in HIV-1 non-B strains infecting drug-naive villagers of Cameroon | |
| Meister et al. | Efficient inactivation of monkeypox virus by world health organization‒recommended hand rub formulations and alcohols | |
| TR200102024T2 (tr) | Yeni tedavi. | |
| WO2002022076A3 (en) | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids | |
| KR890010562A (ko) | 비루스 감염의 표지 물질로서의 활성 rn 아제 l | |
| WISBORG et al. | Norwegian dentists' knowledge, attitudes, and behavior concerning the HIV | |
| ES2093554A1 (es) | Procedimientos de amplificacion de genoma y mezclas de oligonucleotidos iniciadores para la deteccion y la identificacion de agentes infecciosos relacionados. | |
| Parikh et al. | Complete protection from repeated vaginal SHIV exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine | |
| Chan | HIV-1 superinfection: evidence and impact | |
| WO2002022781A3 (en) | Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy | |
| Toyohama et al. | Kaposi's sarcoma in a human immunodeficiency virus-negative patient treated with corticosteroid for idiopathic thrombocytopenic purpura | |
| TR199902508T2 (xx) | HIV proteaz inhibit�rleri. | |
| Bodsworth et al. | Transmission of hepatitis C virus but not human immunodeficiency virus type 1 following sharing of cleaned injecting equipment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |